BINIMETINIB 15 MG TABLETS
MEKTOVI (binimetinib) is a kinase inhibitor. MEKTOVI (binimetinib) tablets for oral use contain 15 mg of binimetinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate (vegetable source), and colloidal silicon dioxide. The coating contains polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide.
MEKTOVI (binimetinib) Tablets: 15 mg.
Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to the initiation of MEKTOVI. The recommended dosage is 45 mg orally twice daily in combination with encorafenib. Take MEKTOVI with or without food. For patients with moderate or severe hepatic impairment the recommended dose is 30 mg orally twice daily.
MEKTOVI (binimetinib) is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.